.August 12, 2024 03:24:54 AM

Exagen Inc. (NASDAQ:XGN) has reached a new 52-week high of $2.78, with a 42.6% surge in the past month and a 38.7% gain since the beginning of the year. The company has consistently exceeded earnings consensus estimates for the last four quarters, reporting an EPS of -$0.16, surpassing the consensus estimate of -$0.36. Future projections indicate earnings of -$1.03 per share on revenues of $57.05 million for the current fiscal year, with positive growth expected to continue into the next fiscal year. Exagen’s strong performance and outlook position it as a promising investment opportunity in the medical sector.